ACP 001

Drug Profile

ACP 001

Alternative Names: ACP-001; TransCon growth hormone; TransCon PEG growth hormone; TransCon PEG hGH; TransCon PEG somatropin

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Ascendis Pharma
  • Class Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 01 Apr 2017 Safety, immunogenicity, and pharmacokinetics data from the phase I TransCon PEG hGH trial and from two phase II trials ACP001CT002 & ACP001CT004 in Somatotropin deficiency presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 15 Dec 2016 Biomarkers information updated
  • 11 Aug 2016 Phase-III clinical trials in Somatotropin deficiency (In children, Treatment-naive) in USA (SC) (NCT02781727)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top